Leonard Saltz
机构: Professor of Medicine, Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center
每年引用次数
引用次数
引用: 87,979
H-指数: 150
I10-指数 : 438
出版物: 863
Association of adverse events (AEs) with outcomes in early stage colon cancer (CC): An analysis of 10,695 CC patients from the ACCENT database.
Winson Y. Cheung , Thierry Andre , Axel Grothey , Rachel Kerr
Journal of Clinical Oncology 36 3601 -3601
2018
Antibody-Based Therapies for Colorectal Cancer
Ki Young Chung , Leonard B. Saltz
Oncologist 10 ( 9) 701 -709
43
2005
Clinical Use of Camptosar (CPT-11)
Leonard B. Saltz
Oncologist 2 ( 3) 191 -191
1997
Clinical Use of Irinotecan:Current Status and Future Considerations
Leonard B. Saltz
Oncologist 2 ( 6) 402 -409
12
1997
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
Daniel A. Goldstein , Mark J. Ratain , Leonard B. Saltz
JAMA Oncology 6 ( 11) 1694 -1695
8
2020
How to improve toxicity evaluation in clinical trials? Testing new metrics from irinotecan or oxaliplatin-based treatments in metastatic colorectal cancer (mCRC): A pooled analysis from 2,349 patients in ARCAD database.
Christophe Tournigand , Guilherme Lopes , Curtis L. Olswold , Richard Adams
Journal of Clinical Oncology 38 ( 4) 89 -89
1
2020
Receipt and survival outcomes by age following second-line therapy for metastatic CRC (mCRC): Analysis of 5,289 patients from the ARCAD Clinical Trials Program.
Nadine Jackson McCleary , William S Harmsen , Eric VanCutsem , Alberto F Sobrero
Journal of Clinical Oncology 38 6 -6
2020
MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial
Thomas Pavelitz , Lindsay Renfro , Nathan R. Foster , Amber Caracol
PLoS ONE 9 ( 10) e108483
9
2014
How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives.
S. Yousuf Zafar , Lee N. Newcomer , Justin McCarthy , Shelley Fuld Nasso
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 37 ( 37) 35 -39
22
2017
Curative-Intent Treatment for Colorectal Liver Metastases: A Medical Oncologist's Perspective.
Leonard B. Saltz
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting ( 32) 205 -208
2
2012
Neither FDG-PET Nor CT Can Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study
José G. Guillem , Jeannine A. Ruby , Tobias Leibold , Timothy J. Akhurst
Annals of Surgery 258 ( 2) 289 -295
120
2013
Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy.
James D. Smith , Jeannine A. Ruby , Karyn A. Goodman , Leonard B. Saltz
Annals of Surgery 256 ( 6) 965 -972
248
2012
KRAS and Colorectal Cancer: Ethical and Pragmatic Issues in Effecting Real-Time Change in Oncology Clinical Trials and Practice
Charles D. Blanke , Richard M. Goldberg , Axel Grothey , Margaret Mooney
Oncologist 16 ( 8) 1061 -1068
16
2011
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Donna Niedzwiecki , Rian M. Hasson , Heinz‐Josef Lenz , Cynthia Ye
Oncologist 22 ( 1) 107 -114
6
2017
Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma—A New Look at an Old Drug
Diane L. Reidy‐Lagunes , Betty Lung , Brian R. Untch , Nitya Raj
Oncologist 22 ( 9) 1102 -1106
20
2017
Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa , Jean‐Frederic Blanc , Steven Miles , Tom Ganten
Oncologist 22 ( 7) 780
13
2017
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Manickam Janakiraman , Efsevia Vakiani , Zhaoshi Zeng , Christine A. Pratilas
Cancer Research 70 ( 14) 5901 -5911
289
2010
First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.
Andrea Cercek , Leonard B. Saltz
Clinical Colorectal Cancer 7
8
2008
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
Leonard B. Saltz , Neal J. Meropol , Patrick J. Loehrer , Michael N. Needle
Journal of Clinical Oncology 22 ( 7) 1201 -1208
2,202
2004
Doxorubicin and Sorafenib for Treatment of Advanced Hepatocellular Cancer
Ghassan K. Abou-Alfa , Leonard B. Saltz
Gastroenterology 141 ( 3)
6
2011